Alkeon Capital Management’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.4M | Hold |
850,511
| – | – | 0.02% | 73 |
|
|
2025
Q1 | $8.67M | Sell |
850,511
-250,489
| -23% | -$2.55M | 0.02% | 73 |
|
|
2024
Q4 | $17.4M | Sell |
1,101,000
-796,601
| -42% | -$12.6M | 0.04% | 63 |
|
|
2024
Q3 | $110M | Buy |
1,897,601
+298,694
| +19% | +$17.3M | 0.19% | 42 |
|
|
2024
Q2 | $73.1M | Hold |
1,598,907
| – | – | 0.12% | 53 |
|
|
2024
Q1 | $106M | Buy |
1,598,907
+100,000
| +7% | +$6.62M | 0.18% | 43 |
|
|
2023
Q4 | $59.6M | Sell |
1,498,907
-177,615
| -11% | -$7.06M | 0.13% | 52 |
|
|
2023
Q3 | $53.4M | Hold |
1,676,522
| – | – | 0.1% | 60 |
|
|
2023
Q2 | $67.4M | Sell |
1,676,522
-1,496
| -0.1% | -$60.1K | 0.12% | 54 |
|
|
2023
Q1 | $71.7M | Buy |
1,678,018
+285,616
| +21% | +$12.2M | 0.16% | 52 |
|
|
2022
Q4 | $66.9M | Buy |
1,392,402
+183,580
| +15% | +$8.82M | 0.26% | 52 |
|
|
2022
Q3 | $45.5M | Buy |
1,208,822
+32,389
| +3% | +$1.22M | 0.15% | 70 |
|
|
2022
Q2 | $32.5M | Buy |
1,176,433
+270,000
| +30% | +$7.46M | 0.09% | 79 |
|
|
2022
Q1 | $49.3M | Sell |
906,433
-20,000
| -2% | -$1.09M | 0.1% | 84 |
|
|
2021
Q4 | $54.2M | Buy |
926,433
+225,000
| +32% | +$13.2M | 0.1% | 88 |
|
|
2021
Q3 | $27.7M | Sell |
701,433
-2,006
| -0.3% | -$79.4K | 0.05% | 106 |
|
|
2021
Q2 | $29.9M | Buy |
703,439
+180,000
| +34% | +$7.64M | 0.04% | 97 |
|
|
2021
Q1 | $32.2M | Buy |
523,439
+1,318
| +0.3% | +$81.1K | 0.05% | 95 |
|
|
2020
Q4 | $36.8M | Buy |
522,121
+492,121
| +1,640% | +$34.7M | 0.06% | 98 |
|
|
2020
Q3 | $1.16M | Hold |
30,000
| – | – | ﹤0.01% | 121 |
|
|
2020
Q2 | $1.13M | Buy |
+30,000
| New | +$1.13M | ﹤0.01% | 122 |
|